Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Declines By 5.9%

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 16,070,000 shares, a drop of 5.9% from the September 30th total of 17,080,000 shares. Based on an average daily trading volume, of 5,230,000 shares, the days-to-cover ratio is presently 3.1 days.

Insider Activity

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jerrold B. Grossman sold 136,861 shares of the business’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the completion of the transaction, the director now directly owns 467,305 shares of the company’s stock, valued at $8,070,357.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. USA Financial Formulas raised its position in ADMA Biologics by 8.6% during the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 539 shares during the period. Vontobel Holding Ltd. raised its holdings in ADMA Biologics by 7.0% during the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 888 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of ADMA Biologics by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after buying an additional 1,509 shares during the last quarter. Quest Partners LLC bought a new stake in shares of ADMA Biologics during the 2nd quarter worth about $29,000. Finally, Arizona State Retirement System increased its holdings in shares of ADMA Biologics by 4.5% during the 2nd quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock valued at $689,000 after acquiring an additional 2,645 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Trading Up 1.5 %

Shares of ADMA stock opened at $16.96 on Thursday. ADMA Biologics has a 1 year low of $3.23 and a 1 year high of $21.13. The stock has a fifty day moving average of $17.87 and a two-hundred day moving average of $13.22. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The firm has a market capitalization of $3.93 billion, a PE ratio of -848.00 and a beta of 0.62.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same quarter last year, the business earned ($0.02) earnings per share. The business’s revenue for the quarter was up 78.4% on a year-over-year basis. As a group, research analysts expect that ADMA Biologics will post 0.49 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ADMA. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of ADMA Biologics in a research note on Monday, October 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ADMA Biologics has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.